BOSULIF

Product Overview

About BOSULIF

BOSULIF is a medicine that contains the active ingredient BOSUTINIB (BOSUTINIB MONOHYDRATE), a tyrosine kinase inhibitor. It is primarily used in the treatment of certain types of cancer, specifically chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) with a specific genetic mutation. BOSULIF works by blocking certain enzymes that promote cancer cell growth, thereby slowing or stopping the growth of cancer cells.

Key Benefits & Uses

• Treatment of chronic myelogenous leukemia (CML) in patients who are resistant or intolerant to prior therapy
• Treatment of acute lymphoblastic leukemia (ALL) with a specific genetic mutation
• Blocks certain enzymes that promote cancer cell growth, slowing or stopping the growth of cancer cells

Active Ingredient & Action

BOSUTINIB (BOSUTINIB MONOHYDRATE) is the active ingredient in BOSULIF, which works by inhibiting the activity of certain tyrosine kinases, including BCR-ABL, c-KIT, and SRC family kinases. By blocking these enzymes, BOSULIF helps to slow or stop the growth of cancer cells, leading to an improvement in symptoms and quality of life for patients with CML and ALL.

Important Notes

Patients taking BOSULIF should follow the dosage and administration instructions provided by their healthcare provider. It is essential to monitor for potential side effects, such as gastrointestinal symptoms, fluid retention, and hematologic toxicity. Patients should also be aware of the potential for interactions with other medications and inform their healthcare provider of any other medications they are taking.